Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.38 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14703141 | 0.99 | EPHX2 (0.48) | EPHX2HRH3SMN1; SMN2POLBTSHR | |
| SCHEMBL14703674 | 0.87 | PHGDH (0.40) | EPHX2HRH3SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14703252 | 0.86 | SMN1; SMN2 (0.46) | EPHX2SMN1; SMN2ALDH1A1 | |
| SCHEMBL28487664 | 0.85 | HRH3 (0.45) | EPHX2HRH3SMN1; SMN2POLBTSHR | |
| SCHEMBL14703673 | 0.85 | ALDH1A1 (0.47) | HRH3SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL14703140 | 0.85 | ALDH1A1 (0.47) | HRH3SMN1; SMN2MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL18191032 | 0.84 | HRH3 (0.44) | EPHX2HRH3SMN1; SMN2POLBTSHR | |
| SCHEMBL14703437 | 0.83 | ALDH1A1 (0.45) | HRH3SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL14703368 | 0.83 | SCN3A (0.39) | EPHX2SMN1; SMN2TSHRRAB9AALDH1A1 | |
| SCHEMBL14703370 | 0.82 | ALDH1A1 (0.46) | MEN1KMT2ARAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742020-B1 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | IMMUNOMET THERAPEUTICS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9321742-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321742-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20140179661-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | HANALL BIOPHARMA CO., LTD. (KR) | 2014-06-26 | — | — | US | disclosed |
| US-20140179661-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | HANALL BIOPHARMA CO., LTD. (KR) | 2014-06-26 | — | — | US | disclosed |
| WO-2013022279-A2 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO., LTD. (KR) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179661-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | PRKAG1, GCKR, GPR119 | EPHX2 4387/4885HRH3 3910/4885SMN1; SMN2 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.